Prostate Cancer Treatment: Evidence-Based Risk-Stratified Management Guide — Cost, Top Hospitals & Success Rates | MyMedicPlus

Prostate cancer is the second most common malignancy in men worldwide, with approximately 1.4 million new diagnoses each year. Treatment strategy is primarily guided by the D'Amico risk stratification system, which categorises localised disease into four groups based on pre-treatment PSA level, Gleason score (ISUP grade group), and clinical T-stage.

• Low risk: PSA <10 ng/mL, Gleason ≤6 (ISUP 1), clinical stage cT1–T2a
• Intermediate risk: PSA 10–20 ng/mL, Gleason 7 (ISUP 2–3), or cT2b
• High risk: PSA >20 ng/mL, Gleason 8–10 (ISUP 4–5), or cT2c–T3a
• Very high / locally advanced: cT3b–T4, N1 disease, or multiple high-risk features

The Gleason grading system has been updated to ISUP grade groups 1–5 to better convey prognostic significance. Modern staging relies on multiparametric MRI (mpMRI), systematic plus targeted biopsy (PRECISION trial protocol), and increasingly PSMA-PET/CT for accurate nodal and metastatic staging. PSMA-PET/CT detects recurrence at PSA levels as low as 0.2 ng/mL, replacing conventional CT and bone scan in many centres.

PSA (prostate-specific antigen) remains central to detection and monitoring but is prostate-specific rather than cancer-specific. Free-to-total PSA ratio and PSA density refine cancer probability. Germline genetic testing — including BRCA1/2, ATM, CHEK2, and PALB2 — is recommended for all high-risk localised, locally advanced, or metastatic disease, enabling biomarker-driven therapy such as PARP inhibitors for HRR mutations and pembrolizumab for MSI-H tumours, and facilitating cascade testing of family members.

Prostate cancer encompasses a spectrum from indolent localised tumours to aggressive metastatic disease. The main clinical scenarios and their treatment pathways are:

• Localised prostate cancer (cT1–T2, N0M0): Tumour confined to the prostate gland. Curative-intent therapy — active surveillance, surgery, or radiotherapy — is standard. The ProtecT trial demonstrated equivalent 15-year cancer-specific survival across surveillance, radical prostatectomy, and radiotherapy for predominantly low-risk disease.
• Locally advanced prostate cancer (cT3–T4 or pN1): Disease extending beyond the prostatic capsule to seminal vesicles, adjacent structures, or pelvic lymph nodes. Requires combined-modality therapy: dose-escalated EBRT with long-term ADT (18–36 months). Prostatectomy is feasible at experienced centres with acceptable oncological outcomes.
• Metastatic hormone-sensitive prostate cancer (mHSPC): Newly diagnosed metastatic disease or castration-sensitive relapse. ADT combined with a novel hormone agent (darolutamide, enzalutamide, or abiraterone+prednisolone) or docetaxel significantly improves overall survival versus ADT monotherapy in pivotal phase III trials.
• Metastatic castration-resistant prostate cancer (mCRPC): Defined as PSA or radiological progression despite castrate testosterone levels (<50 ng/dL). Multiple sequential therapies are available including androgen-receptor signalling inhibitors, taxane chemotherapy, PARP inhibitors, and lutetium-177-PSMA.
• MSI-H / dMMR prostate cancer: A subset (<5% of cases) with microsatellite instability or mismatch repair deficiency, eligible for pembrolizumab immunotherapy regardless of PD-L1 expression under FDA accelerated approval.

Biochemical recurrence (BCR) — PSA ≥0.2 ng/mL on two occasions post-prostatectomy, or nadir+2 ng/mL post-radiotherapy (Phoenix criteria) — represents an important intermediate state requiring PSMA-PET/CT restaging and salvage therapy assessment.

Treatment selection integrates tumour characteristics, patient performance status, life expectancy, comorbidities, and individual preferences following multidisciplinary team (MDT) discussion and shared decision-making.

• Active surveillance (AS): Recommended for low-risk and selected favourable intermediate-risk disease meeting PRIAS criteria: PSA ≤10 ng/mL, ISUP grade 1, ≤2 positive cores, <50% core involvement, PSA density <0.2 ng/mL/cc. The ProtecT trial confirms oncological safety at 15 years with 97% prostate cancer-specific survival regardless of treatment allocation.
• Radical prostatectomy (RARP): Suitable for localised and locally advanced disease in patients with life expectancy ≥10 years and ECOG PS 0–1. Bilateral nerve-sparing is appropriate where oncologically safe (low/intermediate risk, no extracapsular extension on MRI).
• External beam radiotherapy (EBRT): Applicable across all risk groups without strict life expectancy minimum, making it suitable for older or medically unfit patients. High-risk disease requires long-term ADT (18–36 months) co-administration per STAMPEDE and RTOG guidelines.
• SBRT (PACE-B trial criteria): Low- or intermediate-risk localised disease with prostate volume <100 cc (ideally <60 cc), IPSS <15, and no prior pelvic radiotherapy. Five fractions of 7.25 Gy (36.25 Gy total) delivered over 1–2 weeks.
• Brachytherapy: LDR seed implant appropriate for low-risk and selected intermediate-risk disease (prostate volume <60 cc, IPSS <12). HDR brachytherapy boost combined with EBRT is indicated for high-risk disease, providing dose escalation without increasing toxicity to surrounding structures.
• Systemic therapies (mHSPC/mCRPC): Renal, hepatic, cardiovascular, and haematological parameters assessed before initiating novel hormone agents. BRCA1/2 and HRR mutation status (germline and somatic) required before prescribing PARP inhibitors. PSMA-PET/CT and PSMA expression confirmation required for lutetium-177-PSMA eligibility.

Localised Disease

• Active surveillance (PRIAS protocol): PSA every 3 months for 2 years, then every 6 months; mpMRI annually; repeat biopsy at 12 months and per protocol thereafter (or MRI-triggered). Approximately 50–60% of low-risk patients remain on AS at 10 years without active treatment. Reclassification to ISUP ≥3 or PSA doubling time <3 years triggers conversion to curative therapy.
• Robotic-assisted radical prostatectomy (RARP): Now the predominant surgical approach at high-volume centres. Equivalent oncological outcomes to open RP with lower blood loss and faster recovery. Lymph node dissection recommended for intermediate/high-risk disease. Target: undetectable PSA (<0.05 ng/mL) at 6–8 weeks confirms complete resection.
• SBRT (PACE-B trial): 36.25 Gy in 5 fractions over 1–2 weeks. Non-inferior to conventional RT for 2-year biochemical failure-free survival (95.8% vs 94.6%). Dramatically fewer hospital visits improve patient convenience and cost-effectiveness.
• LDR brachytherapy: Iodine-125 or palladium-103 seeds implanted under TRUS-guided transperineal template. D90 prescription dose 145 Gy. Fifteen-year biochemical control rates of 85–90% reported for low-risk disease monotherapy.

High-Risk / Locally Advanced / mHSPC

• Dose-escalated EBRT + ADT: 74–80 Gy with image-guided IMRT/VMAT plus 18–36 months ADT (STAMPEDE/RTOG 0521). HDR brachytherapy boost (15 Gy ×2 fractions) combined with EBRT reduces biochemical failure without increasing grade 3+ toxicity.
• ADT + novel hormone agents (mHSPC): Darolutamide + ADT + docetaxel (ARASENS), enzalutamide + ADT (ENZAMET), abiraterone+prednisolone + ADT (LATITUDE, STAMPEDE) each reduce risk of death by 30–38% versus ADT alone or ADT+docetaxel.

mCRPC

• Olaparib (PROfound trial): PARP inhibitor approved for HRR-mutated mCRPC (BRCA1/2, ATM) post-novel hormone agent. Imaging-based PFS 7.4 vs 3.6 months; confirmed OS benefit (19.1 vs 14.7 months in BRCA1/2 cohort). Dose: 300 mg twice daily.
• Lutetium-177-PSMA-617 (VISION trial): PSMA-positive mCRPC post-ARSI and docetaxel. Six cycles every 6 weeks. Improved OS by 4 months (15.3 vs 11.3 months) and rPFS by 5.3 months. PSA50 response in 46% of patients.
• Pembrolizumab: FDA-approved for MSI-H/dMMR mCRPC regardless of prior therapy. ORR 33% in KEYNOTE-199; responses often durable. Requires MSI/dMMR testing by validated immunohistochemistry or NGS assay.

Modern prostate cancer treatment offers excellent outcomes when matched to appropriate patient and tumour characteristics:

• Active surveillance: Avoids immediate treatment toxicity in 50–65% of low-risk patients who do not require active treatment within 10 years. ProtecT 15-year follow-up confirms 97% prostate cancer-specific survival — statistically equivalent to immediate RP or RT — demonstrating that careful monitoring is not a compromise of cure in appropriately selected patients.
• Radical prostatectomy (RARP): Ten-year biochemical progression-free survival of 70–90% for localised low/intermediate-risk disease. Pathological staging provides definitive information unavailable pre-operatively. Nerve-sparing technique preserves potency in 50–75% of men with normal pre-operative function at experienced centres.
• Dose-escalated EBRT + ADT: Addition of abiraterone+prednisolone to ADT in high-risk localised disease (STAMPEDE) reduces 5-year failure from 61% to 39%. Long-term ADT (18–36 months) doubles biochemical progression-free survival versus short-course ADT (6 months) in RTOG 0521.
• SBRT (PACE-B): Non-inferior at 2 years for biochemical control with equivalent patient-reported outcomes (EPIC-26 at 2 years). Five treatment fractions versus 20–39 with conventional RT.
• ADT + darolutamide (ARASENS): Reduced risk of death by 32% (HR 0.68; 95% CI 0.57–0.80) versus docetaxel + ADT. OS 63% vs 50% at 4 years.
• ADT + abiraterone+prednisolone (LATITUDE): Reduced risk of death by 34% (HR 0.66); 5-year OS 53% vs 36% with ADT alone.
• Olaparib (PROfound BRCA1/2 cohort): 57% reduction in risk of imaging progression or death. Confirmed OS benefit with median OS 19.1 vs 14.7 months.
• Lutetium-177-PSMA (VISION): Significant OS improvement (15.3 vs 11.3 months) and rPFS improvement (8.7 vs 3.4 months) in heavily pre-treated PSMA-positive mCRPC.

Each treatment carries a distinct toxicity profile that should be balanced against individual patient priorities during shared decision-making:

• Radical prostatectomy: Erectile dysfunction (40–80% depending on nerve-sparing technique and baseline function); urinary incontinence requiring pads in <5% long-term after bilateral nerve-sparing; anastomotic stricture (2–5%); lymphocele if extended pelvic lymph node dissection (up to 10%); VTE risk perioperatively requiring LMWH prophylaxis.
• External beam radiotherapy: Acute radiation proctitis (diarrhoea, rectal urgency) and cystitis during treatment; late bowel toxicity grade ≥2 in 5–15%; late urinary toxicity including haematuria and urethral stricture; second malignancy risk <0.5% lifetime excess.
• Brachytherapy: Acute urinary retention requiring catheterisation (5–15%); dysuria and frequency resolving within 6–12 months; late urethral stricture <3%; seed migration (pulmonary emboli reported rarely); LDR radiation precautions for close contacts for 2–3 months post-implant.
• Androgen deprivation therapy (ADT): Hot flashes (80%); loss of libido and erectile dysfunction; fatigue; osteoporosis (BMD loss 2–5%/year — DEXA monitoring and bone protective agents indicated); metabolic syndrome, type 2 diabetes mellitus; cardiovascular risk (coronary artery disease); cognitive effects; anaemia (usually mild); gynaecomastia.
• Abiraterone + prednisolone: Hypertension, hypokalaemia, fluid retention, hepatotoxicity (monthly LFT monitoring required). Mineralocorticoid excess managed by prednisolone 5 mg/day co-prescription.
• Enzalutamide / darolutamide: Fatigue, hypertension, falls risk in elderly. Seizure risk <1% with enzalutamide; lower CNS penetration with darolutamide reduces this. Caution in seizure history.
• Olaparib: Anaemia requiring dose reduction or transfusion (grade 3–4 in ~20%); nausea; fatigue; MDS/AML risk (<1%). Full blood count monitoring every 4 weeks for first 12 months.
• Lutetium-177-PSMA: Dry mouth/xerostomia (86% any grade, 8% grade 3); nausea; fatigue; haematological toxicity (thrombocytopenia, anaemia); very rare radiation nephritis. Hydration and salivary gland cooling may attenuate xerostomia.

Structured post-treatment surveillance enables early detection of biochemical recurrence, management of late toxicity, and timely initiation of salvage therapy:

After radical prostatectomy:

• PSA at 6–8 weeks; target: undetectable (<0.05 ng/mL, or <0.01 ng/mL by ultrasensitive assay)
• PSA every 3–6 months for 2 years, then every 6 months years 3–5, then annually
• BCR defined as two consecutive PSA values ≥0.2 ng/mL. PSMA-PET/CT before salvage RT decision.
• Salvage radiotherapy ± ADT recommended promptly at PSA <0.5 ng/mL for optimal outcomes (RADICALS-RT trial)

After radiotherapy (EBRT/SBRT/brachytherapy):

• PSA every 6 months for 5 years, then annually
• PSA nadir reached 18–24 months post-EBRT; target <0.5 ng/mL for SBRT
• BCR by Phoenix criteria: PSA nadir + 2 ng/mL on two consecutive measurements
• EPIC-26 patient-reported quality-of-life outcomes at 12 and 24 months

On active surveillance:

• PSA every 3 months for 2 years, then every 6 months
• mpMRI at 12–18 months and every 1–2 years thereafter
• Confirmatory repeat biopsy at 12 months; subsequent biopsies per PRIAS protocol or if PSA kinetics deteriorate
• Grade group reclassification to ISUP ≥3 or PSA doubling time <3 years triggers transition to active treatment

Metastatic / systemic disease:

• PSA, LFTs, FBC, serum testosterone every 3–4 months on ADT
• DEXA bone densitometry at baseline and 1–2 yearly; bone-protective agent if T-score <–1.0
• CT chest-abdomen-pelvis + bone scan (or PSMA-PET/CT) every 3–6 months for mCRPC
• Early integration of specialist palliative care for symptomatic metastatic disease alongside disease-directed therapy

Prostate cancer treatment costs vary substantially by modality, country, and healthcare system. The following estimates reflect typical private-pay costs and are for guidance only:

• Active surveillance: Ongoing monitoring: PSA testing (~$20–50 per test), mpMRI (~$800–1,500 per scan), prostate biopsy ($1,500–3,500). Total 5-year monitoring costs may reach $15,000–30,000 in the US private setting, but surveillance avoids immediate treatment expenditure for the majority of low-risk patients.
• Radical prostatectomy (RARP): US private: $20,000–40,000 (surgeon, facility, anaesthesia, 1–2 day stay). NHS England: fully funded. Medical tourism: India $4,000–8,000; Thailand $8,000–12,000; Turkey $6,000–10,000 at accredited centres.
• External beam radiotherapy (IMRT/VMAT): US private: $25,000–55,000 for 39-fraction course. Hypofractionation (20 fractions) reduces cost proportionally. SBRT (5 fractions) $15,000–25,000 in the US; cost-effective per QALY versus conventional RT.
• Brachytherapy: LDR seed implant $10,000–18,000 (day-case). HDR boost requires 1–2 night admission, adding $3,000–5,000.
• ADT (LHRH agonists): Monthly leuprolide or goserelin $300–600/month. Generic leuprolide significantly cheaper. Six-monthly depots more convenient.
• Novel hormone agents: Brand enzalutamide ~$17,000/month; brand abiraterone ~$10,000/month (generic abiraterone substantially cheaper in most markets). Darolutamide ~$20,000/month. NHS-funded under NICE technology appraisals for eligible patients.
• Olaparib: ~$17,000/month in the US; NHS-funded for BRCA1/2-mutated mCRPC under NICE TA777.
• Lutetium-177-PSMA (6 cycles total): US total course ~$250,000. Medicare-funded in the US. NHS England-funded from 2023 for VISION-eligible patients. India: ~$10,000–15,000 per cycle at accredited centres.

Medical travel to accredited oncology centres in India, Thailand, Turkey, and Mexico can reduce surgical and radiotherapy costs by 60–80% compared to US private rates while maintaining high clinical standards at JCI- or NABH-accredited facilities.

Several alternative and investigational approaches are available for selected patients:

• Focal therapy — HIFU (high-intensity focused ultrasound): Whole-gland or hemi-ablation targeting the index lesion using Ablatherm or Sonablate devices. Five-year biochemical failure rates in low/intermediate-risk disease are comparable to whole-gland treatments in selected series, with significantly lower rates of erectile dysfunction and incontinence. NICE IPG424 recommends use within a research registry; not yet standard of care. PARTE randomised trial ongoing.
• Cryotherapy (cryoablation): Primary focal or salvage whole-gland freezing. Particularly useful as salvage therapy after radiotherapy failure, where surgical salvage carries high morbidity. Higher rates of ED (60–80%) and urethral sloughing than HIFU. EAU Guidelines recommend as an option in selected patients.
• Vascular-targeted photodynamic therapy (WST11 — TOOKAD Soluble): For low-risk localised disease; the PCM301 randomised trial showed improved 2-year disease-free survival versus active surveillance (49% vs 14% negative biopsy conversion at 2 years). Not yet widely available outside specialist centres.
• Clinical trials (mCRPC): All patients with mCRPC should be considered for enrolment. Key ongoing trials include: olaparib + pembrolizumab (KEYLYNK-010 for all-comers mCRPC), actinium-225-PSMA-617 (ALPHA trial for high-activity alpha-emitter theranostics), PSMA-targeting bi-specific T-cell engagers (AMG 160, JNJ-63898081), and PSMA-directed CAR-T cell therapies in early-phase studies.
• Exercise oncology and lifestyle: Structured exercise programmes (aerobic + resistance training) reduce ADT-related sarcopenia, bone mineral density loss, cardiovascular risk, and cancer-related fatigue, with level 1 evidence for improved cancer-specific and all-cause survival in prostate cancer. Mediterranean diet is associated with reduced biochemical recurrence in observational data. No specific dietary supplement has demonstrated cancer-modifying efficacy in randomised controlled trials.